Because these results have not been previously reported in breast cancer cells, our studies present preliminary evidence that TRPM2 is a potential therapeutic target in breast cancer and its pharmacologic inhibition is expected to selectively target breast cancer cells. Here, TRPM2 is linked to breast carcinoma.